NasdaqGM:RLAYBiotechs
Relay Therapeutics (RLAY) Is Down 14.9% After Zovegalisib Triplet Data And Phase 3 Plans With Pfizer – Has The Bull Case Changed?
Relay Therapeutics recently reported encouraging Phase 1/2 data for its lead asset zovegalisib in heavily pre-treated PI3Ka‑mutated HR+/HER2- metastatic breast cancer and outlined plans, subject to regulatory feedback, to launch a Phase 3 trial in collaboration with Pfizer’s investigational CDK4 inhibitor atirmociclib.
At the same time, Relay is seeking shareholder approval to increase its authorized common stock pool and is seeing strong interest from Wall Street analysts, underscoring how...